Efficacy and safety of eflornithine (CPP-1X)/sulindac combination therapy versus each as monotherapy in patients with familial adenomatous polyposis (FAP): design and rationale of a randomized, double-blind, Phase III trial.
about
Ornithine decarboxylase as a therapeutic target for endometrial cancer.Alpha-Difluoromethylornithine, an Irreversible Inhibitor of Polyamine Biosynthesis, as a Therapeutic Strategy against Hyperproliferative and Infectious Diseases.Polyamines and Cancer.Clinically Relevant Anti-Inflammatory Agents for Chemoprevention of Colorectal Cancer: New Perspectives
P2860
Efficacy and safety of eflornithine (CPP-1X)/sulindac combination therapy versus each as monotherapy in patients with familial adenomatous polyposis (FAP): design and rationale of a randomized, double-blind, Phase III trial.
description
2016 nî lūn-bûn
@nan
2016 թուականի Օգոստոսին հրատարակուած գիտական յօդուած
@hyw
2016 թվականի օգոստոսին հրատարակված գիտական հոդված
@hy
2016年の論文
@ja
2016年論文
@yue
2016年論文
@zh-hant
2016年論文
@zh-hk
2016年論文
@zh-mo
2016年論文
@zh-tw
2016年论文
@wuu
name
Efficacy and safety of eflorni ...... double-blind, Phase III trial
@nl
Efficacy and safety of eflorni ...... double-blind, Phase III trial.
@ast
Efficacy and safety of eflorni ...... double-blind, Phase III trial.
@en
type
label
Efficacy and safety of eflorni ...... double-blind, Phase III trial
@nl
Efficacy and safety of eflorni ...... double-blind, Phase III trial.
@ast
Efficacy and safety of eflorni ...... double-blind, Phase III trial.
@en
prefLabel
Efficacy and safety of eflorni ...... double-blind, Phase III trial
@nl
Efficacy and safety of eflorni ...... double-blind, Phase III trial.
@ast
Efficacy and safety of eflorni ...... double-blind, Phase III trial.
@en
P2093
P2860
P3181
P1433
P1476
Efficacy and safety of eflorni ...... double-blind, Phase III trial.
@en
P2093
Alfred Cohen
Carol A Burke
Elena Stoffel
N Jewel Samadder
P2860
P2888
P3181
P356
10.1186/S12876-016-0494-4
P407
P577
2016-08-02T00:00:00Z
P6179
1020689210